Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00414128
Other study ID # MYCYC
Secondary ID Eudract: 2006-00
Status Completed
Phase Phase 2/Phase 3
First received December 19, 2006
Last updated December 5, 2013
Start date March 2007
Est. completion date February 2013

Study information

Verified date December 2013
Source Cambridge University Hospitals NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority European Union: European Medicines Agency
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate whether mycophenolate mofetil is effective as treatment for new cases of ANCA associated vasculitis.


Description:

There is a clear need for improved therapy in ANCA associated vasculitis where current treatments are toxic and contribute to poor outcomes. Conventional therapy combines cyclophosphamide with prednisolone but is associated with severe adverse events in 35%, early mortality, malignancy and infertility. Mycophenolate mofetil (MMF) is a newer immunosuppressive drug which has superior efficacy to azathioprine in solid organ transplantation. MMF is an effective alternative to cyclophosphamide in lupus nephritis. Open label studies and retrospective surveys point to the efficacy and low toxicity of MMF in vasculitis.

We hypothesise that MMF not be less effective than cyclophosphamide for remission induction in AASV. 140 new patients will be randomised to MMF 3g/day or a European consensus intravenous cyclophosphamide regimen, with the same prednisolone dosing. Following a six month induction course all patients will receive consensus remission maintenance treatment with azathioprine and prednisolone. The primary end-point will be remission rate by six months, secondary end-points include relapse rate at 18 months and safety. The trial will be conducted in 10 countries by members of the European Vasculitis Study Group (EUVAS). The trial duration will be 42 months (24 months recruitment, 18 months follow up).


Recruitment information / eligibility

Status Completed
Enrollment 140
Est. completion date February 2013
Est. primary completion date July 2011
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

Inclusion (requires all):

- New diagnosis of AASV (WG or MPA) (within the previous six months)

- Active disease (defined by at least one major or three minor BVAS 2003 items, see appendix 1)

- ANCA positivity (c-ANCA and PR3-ANCA or p-ANCA and MPO-ANCA) or histology confirming active vasculitis from any organ (see appendix )

- Written informed consent

Exclusion Criteria:

- Previous treatment with:

- MMF: more than two weeks ever.

- Cyclophosphamide: more than two weeks daily oral or more than 1 pulse of IV CYC (15mg/kg)

- Rituximab or high dose intravenous immunoglobulin within the last twelve months

- Active infection (including hepatitis B, C, HIV and tuberculosis).

- Known hypersensitivity to MMF, AZA or CYC.

- Cancer or an individual history of cancer (other than resected basal cell skin carcinoma).

- Females who are pregnant, breast feeding, or at risk of pregnancy and not using a medically acceptable form of contraception.

- Any condition judged by the investigator that would cause the study to be detrimental to the patient.

- Any other multi-system autoimmune disease including Churg Strauss angiitis, SLE, anti GBM disease and cryoglobulinaemia.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
mycophenolate mofetil
2-3g/day for 3-6 months, in tablet, capsule or liquid form
cyclophosphamide
intravenous cyclophosphamide, 15mg/kg with dose reductions according to age and renal function, for 3-6 months (6-10 doses total)

Locations

Country Name City State
United Kingdom Addenbrookes Hospital Cambridge Cambridgeshire

Sponsors (3)

Lead Sponsor Collaborator
Cambridge University Hospitals NHS Foundation Trust Aspreva Pharmaceuticals, Vifor Pharma

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Remission rates at 6 months Assessed by BVAS score of zero on 2 consecutive assessments 6 months No
See also
  Status Clinical Trial Phase
Recruiting NCT02498808 - Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases? N/A
Completed NCT01363388 - A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis Phase 2
Completed NCT00004357 - Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Phase 2
Recruiting NCT05263817 - A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis Early Phase 1
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed NCT01947465 - Immunogenicity and Safety of Vaccinations in Immunocompromised Persons N/A
Completed NCT02240888 - Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response N/A
Completed NCT03693586 - Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis
Completed NCT05604482 - CXCR4-PET/CT for Diagnosing Giant Cell Arteritis N/A
Completed NCT03765424 - Evaluation of Ultrasound and PET/CT in the Diagnosis and Monitoring of Giant Cell Arteritis
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Recruiting NCT05383339 - Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases
Active, not recruiting NCT03755245 - Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis N/A
Recruiting NCT05565885 - Search for BIO Diagnostic and Prognostic Markers in Adult VAScularitis
Recruiting NCT02593565 - Vasculitis Pregnancy Registry
Recruiting NCT02856243 - Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis N/A
Recruiting NCT05628948 - Vascular Lab Resource (VLR) Biorepository
Active, not recruiting NCT03692416 - The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children Phase 3
Completed NCT05115370 - Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19
Terminated NCT03937856 - Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases N/A

External Links